Endo International to acquire BioSpecifics Technologies in $658m deal
In a strategic move to strengthen its portfolio, Endo International has reached an agreement to acquire BioSpecifics Technologies,…
Bracco Diagnostics secures FDA approval for new CardioGen-82 infusion system: A major advancement in cardiac PET imaging
Bracco Diagnostics, a leading US subsidiary of the renowned Italian diagnostic imaging company Bracco Imaging, has officially received…
Lilly’s acquisition of Disarm Therapeutics: A milestone in neurodegenerative disease treatment
In a significant move to bolster its portfolio in the field of neurological disease treatments, Eli Lilly and…
Oxford University develops rapid diagnostic test for Covid-19 detection in five minutes
A team of scientists from Oxford University’s Physics Department has unveiled a groundbreaking diagnostic test capable of detecting…
Regeneron Pharmaceuticals’ Inmazeb FDA approval: A milestone in Ebola treatment
Regeneron Pharmaceuticals has achieved a significant breakthrough with the approval of its antibody cocktail, Inmazeb (atoltivimab, maftivimab, and…
AstraZeneca’s AZD7442 to enter Phase 3 clinical trials for Covid-19 prevention and treatment
AstraZeneca has announced the progression of its monoclonal antibody combination, AZD7442, into two pivotal Phase 3 clinical trials.…
Pfizer’s IBRANCE fails to meet primary endpoint in PENELOPE-B breast cancer trial
The latest results from Pfizer’s Phase 3 PENELOPE-B clinical trial have cast a shadow over the potential of…
VirTrial partners with BetterLife Pharma to enhance COVID-19 clinical trials through remote patient monitoring
In a significant move to advance clinical research amidst ongoing global health challenges, VirTrial, a leading U.S.-based bioscience…
Bristol Myers Squibb’s Zeposia shows promising results in phase 3 True North trial for ulcerative colitis treatment
Bristol Myers Squibb (BMS) has reported significant success in its phase 3 True North clinical trial, evaluating the…
R3 Vascular secures $17.8m in Series A for bioresorbable vascular scaffolds
R3 Vascular, a promising early-stage medical device company based in the United States, has raised $17.8 million in…